ImmunoGen (IMGN) Q3 Loss Narrower Than Expected, Revenues Lag Posted byZacks Equity Research November 1, 2021 Leave a comment on ImmunoGen (IMGN) Q3 Loss Narrower Than Expected, Revenues Lag ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. The company lowers its operating expense guidance for 2021.